Meridian Bioscience: Falls after FDA seeks additional data on COVID-19 test
16/02/2021 17:22
** Shares of diagnostic test kit maker VIVO.O tumble about
14% to a near two-week low of $25.64
** VIVO says U.S. FDA has sought additional information on
co's COVID-19 molecular diagnostic test, related to the
emergency use authorization (EUA) application urn:newsml:reuters.com:*:nGNX42rwR6
** Co plans to submit a response to the FDA; says it has
decided to place shipments of the COVID-19 test kits on hold
while it continues to work with the FDA
** Co submitted an EUA application for the test in December
last year [https://bit.ly/3b9C0Fe
]
** Stock had risen 59.6% YTD as of its last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))